News & Announcements

Weil Serves as Antitrust Counsel to Allergan in the Acquisition of KYTHERA

Weil’s Antitrust team is representing Allergan plc, a leading global pharmaceutical company, in its recently announced acquisition of KYTHERA Biopharmaceuticals Inc., a transaction valued at approximately $2.1 billion. The transaction is subject to antitrust regulatory approval as well as customary closing conditions, and is expected to close in the third quarter of 2015.  KYTHERA “focuse[s] on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.”

Weil’s Antitrust team includes partners Steven Newborn and Ann Malester and associates Brianne Kucerik, Meaghan Thomas-Kennedy, and Benjamin Bauer.